move acquir ge biopharma busi net tax benefit mark
capit deploy event investor wait view deal
perfect fit solidifi leadership bioprocess see
one best secular growth area healthcar ebitda valuat
attract prior pll/cphd deal pt anticip
acquir ge biopharma asset
acquir ge biopharma asset net npv tax benefit
largest deal ever biggest sinc pll deal financ
equiti new debt/cash expect adj ep
accret hsd expect deal close
 anti-trust issu
deal check box attract target lead brand high
high recur rev power secular growth driver room margin
expans less obviou ebitda margin expect
least cost synergi less initi pll target combin
pll biopharma unit deal solidifi biggest global player
bioprocess move lift life unit pf mix similar
cphd/phenomenx/idt build strateg portfolio shift toward higher-
growth market ad growth profil
ge domin player bioprocess well-posit benefit rise
biolog total drug sale grow hsd adopt single-us solut
great market product spec product process
rare ever chang life-cycle drug creat sticki annuiti
stream ge expect gener rev growth compris
capit deploy unlik time
follow deal figur gross leverag ratio rise pf ebitda
gener signific last time use equiti financ
acquisit bec proceed repurchas entir amount
within two yr close surpris see time
rais pt
page highlight pf est valuat revis pt impli pf
ebitda pf ep similar ftm multipl today
slight premium tool peer
note estim includ contribut
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
price impli pf ep
acceler synergi captur recent
price impli pf ep
slower expect synergi captur recent
price impli pf ep
dhr dramat portfolio evolut escal secular
organ revenu growth profil reduc
enterpris oper volatil consider exposur
favor secular growth dynam way life scienc
diagnost dental market key invest merit
view
close acquisit
spin dental divis
pleas see import disclosur inform page report
financi summari market data
estim valuat
note estim includ contribut
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
diversifi global scienc technolog portfolio compani lead brand oper health care life scienc
research diagnost dental biopharmaceut manufactur environment water qualiti industri product id industri
complet spin-off legaci industri busi test measur retail/commerci petroleum industri
new independ compani juli
pt repres horizon dcf impli nopat compound-annual-growth-rate pf ep risk macro care
util reimburs asp pressur diagnost misstep china/tariff
brandon couillard certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
matthew stanton certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
michael koban certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
pleas see import disclosur inform page report
